anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to an apple polyphenol capsule. The capsule is formed by covering apple polyphenols with a film forming material. The film forming material comprises glucomannan, sodium alginate, chitosan and CaCl2. A preparing method of the slow-release capsule includes: (1) a step of preparing a composite sol solution, (2) a step of preparing a composite solution; and (3) a step of preparing the slow-release capsule, namely a step of mixing an apply polyphenol solution having a formula amount with the composite sol solution in the step (1) according to a volume ratio of a formula, adding the mixture into the composite solution in the step (2), mixing and filtering to obtain a solid that is the slow-release capsule. The slow-release capsule is prepared from the natural apple polyphenols with antihypertensive effects, glucomannan with blood glucose reducing effects, and other natural extract products, and is nontoxic to human bodies. By utilization of the swelling property of the glucomannan, the slow-release capsule swells slowly after entering the gastrointestinal tract, rapid dissolution of polyphenols is inhibited, and stabilization of the polyphenols is facilitated.
DNA highly frequently expressed in mesangial cells, and a protein (meg-1) encoded by this DNA.  These substances are useful in identifying mesangial cells, detecting abnormalities in mesangial cells, etc. Moreover, the function of mesangial cells is clarified based on the function of the above protein. It is therefore expected that the causes of diseases concerning mesangial cell will be discovered thereby. These substances are also expected as being applicable to the treatment, diagnosis, etc. of diseases concerning mesangial cells.
A substantially pure receptor with binding activity for rhinoviruses of the minor human receptor group is disclosed, which has the following characteristics: (a) a molecular weight of 120 kD on a polyacrylamide gel in the presence of SDS; (b) a sedimentation constant, determined by sucrose gradient centrifugation in the presence of detergents, corresponding to about 28.4 S; (c) is bound by Lens culinaris lectin; (d) is not bound by heparin-sepharose; (e) is bound irreversibly to an anion exchanger; (f) has binding activity which is insensitive to neuraminidase; (g) consists of sub-units connected by intermolecular disulfide bridges; (h) shows no binding activity to rhinoviruses in the presence of EDTA; and (i) has a binding activity to rhinoviruses which is only slightly influenced by iodoacetamide. A receptor subunit of the above-described receptor, produced by complete reduction of said receptor, is also disclosed. Multimeric forms of the above-described receptor, obtained by controlled oxidation of the monomeric receptor, are also disclosed. Methods of providing protection against infection by rhinoviruses of the minor receptor group with the substantially pure receptor of the present invention, are also disclosed. A method for the production of receptors for the minor rhinovirus receptor group is also disclosed. A pharmaceutical composition and a method of treating rhinovirus infections in a subject is also disclosed.
Monitoring the progression of Alzheimer's disease (AD) is crucial for mitigating dementia symptoms, alleviating pain, and improving mobility. Traditionally, AD biomarkers like amyloid plaques are predominantly identified in cerebrospinal fluid (CSF) due to their concentrated presence. However, detecting these markers in blood is hindered by the blood-brain barrier (BBB), resulting in lower concentrations. To address this challenge and identify pertinent AD biomarkers-specifically amyloid plaques and apolipoprotein E4 (ApoE4)-in blood plasma, we propose an innovative approach. This involves enhancing a screen-printed carbon electrode (SPCE) with an immobilization matrix comprising gold nanostars (AuNSs) coated with chitosan. Morphological and electrical analyses confirmed superior dispersion and conductivity with 0.5% chitosan, supported by UV-Vis spectroscopy, cyclic voltammetry, and Nyquist plots. Subsequent clinical assays measured electrical responses to quantify amyloid-β 42 (Aβ42) (15.63-1000 pg/mL) and APoE4 levels (0.41 to 40 ng/mL) in human blood plasma samples. Differential pulse voltammetry (DPV) responses exhibited peak currents proportional to biomarker concentrations, demonstrating high linear correlations (0.985 for Aβ42 and 0.919 for APoE4) with minimal error bars. Cross-reactivity tests with mixed solutions of amyloid-β 40 (Aβ40), Aβ42, and ApoE4 indicated minimal interference between biomarkers (<3% variation), further confirming the high specificity of the developed sensor. Validation studies demonstrated a strong concurrence with the gold-standard enzyme-linked immunosorbent assay (ELISA), while interference tests indicated a minimal variation in peak currents. This improved device presents promising potential as a point-of-care system, offering a less invasive, cost-effective, and simplified approach to detecting and tracking the progression of AD. The substantial surface binding area further supports the efficacy of our method, offering a promising avenue for advancing AD diagnostics.
Disclosed herein are polynucleotides comprising a first nucleic acid encoding a first pathogen antigen and optionally a second nucleic acid encoding a second pathogen antigen, and optionally a nucleic acid encoding an immunomodulator. In some aspects, the first pathogen antigen is SARS-CoV-2 spike protein or an antigenic fragment thereof. In some aspects, the second pathogen antigen is a SARS-CoV-2 protein or an antigenic fragment thereof. In some aspects, the polynucleotide comprises two or more different immunomodulators. Also disclosed herein are vectors, compositions, pharmaceutical compositions, vaccines, lyophilized compositions, and cells comprising such polynucleotides. Also disclosed herein are methods of manufacture and therapeutic uses.
Group A will be inducted as before in addition of giving a peribulbar block up to 5 ml ( according to the volume of the eye ) of Articaine 4 % with adrenaline 1/100000 mixed with 10IU of Hyaluronidase by a single injection technique: a 26/27 gauge needle will be inserted as far laterally as possible in the inferotemporal quadrant. Once the needle is under the globe, it will be directed along the orbital floor, passing the globe equator to a depth controlled by observing the needle/hub junction reaching the plane of the iris. After negative aspiration for blood, with the globe in primary gaze, and start injection and the injected volume will be guided by digital intraocular pressure.
Carefully consider the potential benefits and risks of ibuprofen and famotidine tablets and other treatment options before deciding to use ibuprofen and famotidine tablets. Use ibuprofen at the lowest effective dosage for the shortest duration consistent with individual patient treatment goals [see Warnings and Precautions (5)]. 

The recommended daily dose of ibuprofen and famotidine 800 mg/26.6 mg is a single tablet administered orally three times per day.

Ibuprofen and famotidine tablets should be swallowed whole, and should not be cut to supply a lower dose. Do not chew, divide, or crush tablets.

Patients should be instructed that if a dose is missed, it should be taken as soon possible. However, if the next scheduled dose is due, the patient should not take the missed dose, and should be instructed to take the next dose on time. Patients should be instructed not to take 2 doses at one time to make up for a missed dose.

Do not substitute ibuprofen and famotidine tablet with the single-ingredient products of ibuprofen and famotidine.
A total number of 40-60 young males aged 18-30 will be initially enrolled in the study. Then, participants will be allocated to either a 1) Low glutathione (GSH-low) or a 2) High glutathione (GSH-high) group based on the basal glutathione levels of their vastus lateralis muscle. In a double-blind, crossover, repeated measures design, participants will consume either Placebo (PLA) or N-acetylcysteine (NAC) before (7-day loading phase), on exercise day and for 8 consecutive days following a single bout of intense exercise (300 eccentric contractions at 30 deg/sec in an isokinetic dynamometer). In both conditions, blood samples and muscle biopsies will be collected at baseline, before the exercise protocol and at 2- and 8-days post-exercise. Muscle performance and soreness will also be assessed at the same time points. Before each trial, participants' dietary intake will be analyzed via diet recalls. Physical activity will be analyzed only at baseline via accelerometry. A 4-week washout period will be implemented between trials. Blood samples will be analyzed for inflammation and oxidative stress markers. Muscle samples will be analyzed for satellite cell responses and myogenic potential, protein levels of intracellular signaling proteins, muscle thiols and antioxidant enzyme activity.
The prevalence of obesity and type 2 diabetes is a serious global health concern. Obesity is a major pathogenic factor in type 2 diabetes, cardiovascular disease, and some cancers. Bariatric surgery offers a long-term and effective treatment option for both obesity and diabetes. Sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) are widely recognized as the most popular bariatric surgeries. Additionally, several exploratory bariatric surgeries have demonstrated promising therapeutic effects. Duodenal-jejunal bypass (DJB), specifically tailored for diabetics with low body mass index, has shown beneficial metabolic outcomes. However, its weight-independent metabolic benefits are not fully understood due to limited animal models. In this article, we describe the optimized care protocols and surgical techniques for performing DJB surgery in diet-induced obese (DIO) diabetic mice. Using a mouse model contributes to a better understanding of the nature of changes induced by DJB surgery while facilitating related clinical practice.
Patients receive atezolizumab IV over 30-60 minutes on day 1, bevacizumab IV over 30-90 minutes on day 1, and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Following a 2 week run-in period, participants were randomized to Sotagliflozin 200 mg administered as 1 sotagliflozin tablet and 1 matching placebo tablet, once daily, before the first meal of the day, for up to 26 weeks in the Core Treatment Period. Participants were eligible to continue treatment in the Extension Period. The total treatment duration was planned for up to 104 weeks.
The invention discloses a Tet-Off Advanced stably expressing human high-transition nasopharyngeal carcinoma cell line S18, a construction method thereof and application thereof. The nasopharyngeal carcinoma cell line with high tetracycline induced and regulated target gene expression capacity is obtained by inducing a Tet-Off Advanced gene into a nasopharyngeal carcinoma cell, screening, resistance cloning and enlarged culture and identification. The nasopharyngeal carcinoma cell line constructed by the method is named Tet-Off Advanced human high-transition nasopharyngeal carcinoma cell line and is preserved in China Center for Typical Culture Collection, and the preservation number is CCTCC C200959. The cell line has stable and sensitive function of regulating the expression of a target gene. When some target gene is required to be studied, the nasopharyngeal carcinoma cell line is transfected with a pTRE-Tight plasmid of the target gene, and after screening, the obtained resistance clone gene is identified and thus the nasopharyngeal carcinoma cell line expressing the target gen under the induction of the tetracycline is obtained. The expression of the target gene can be regulated quantitatively at regular time by simply regulating the tetracycline content of an environment.
Spinal muscular atrophy (SMA) is a neuromuscular disease characterized by degeneration of motor neurons and progressive muscle atrophy. The disease is one of the most common genetic causes of infant death. The gene responsible for SMA, survival motor neuron (SMN), exists in humans as two nearly identical copies (SMN1 and SMN2). Only deletion or mutation(s) of the telomeric copy of the gene (SMN1) causes the disease. The SMN protein has been known to function in assembly of the RNA splicing complex, however, the mechanism(s) by which SMN-deficiency causes cell death in SMA are not clear. The long-term goal is to understand the mechanism(s) of motor neuron death in SMA and develop a means of prevention. SMN protein has been reported to have some survival promoting functions in cultured cells. Preliminary studies show that skin fibroblasts from SMA patients are more sensitive to certain death promoting stimuli than control fibroblasts. The investigators hypothesize that the SMN protein is directly involved in cell survival and that loss of this survival function of SMA results in motor neuron death in SMA. The investigators will use fibroblasts from SMA patients, fibroblasts from controls without SMA, motor neuron-like cell lines (such as NSC-34) and rodent primary motor neuron cultures as model systems to test our hypothesis. The investigators will determine the effect of expression of SMN protein in regulating cell death of SMA fibroblasts. The investigators will further investigate the role of SMN in neuronal cell survival. Finally, the investigators will determine biological pathway(s) of SMN-mediated cell protection. Results from the proposed studies will provide insight into the mechanism(s) by which SMN protects cells from death and how a decrease in SMN function leads to the SMA phenotype. Ultimately, the obtained information could lead to develop therapeutic strategies for SMA.
OBJECTIVE: Immune checkpoint inhibitor (ICI) therapy activates the immune system to recognize and eliminate cancer cells that have escaped surveillance. This study aimed to compare the treatment outcome of advanced and recurrent cervical cancer patients treated with first-line platinum and paclitaxel with or without ICI.
METHODS: Data from 69 advanced and recurrent cervical cancer patients treated with first-line ICI plus platinum and paclitaxel (N = 33) or first-line platinum and paclitaxel (N = 36) were reviewed between March 2020 and January 2023 in this retrospective study. Patients chose treatment based on the actual disease condition, patient willingness, and medical advice. Additionally, objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) were calculated, and adverse events were gained.
RESULTS: There was no difference in baseline data between patients receiving the two different treatments (all P > 0.05). Complete response rate (18.2% vs. 8.3%; P = 0.294), ORR (48.5% vs. 30.6%; P = 0.127), and DCR (81.8% vs. 72.2%; P = 0.345) tended to ascend in patients treated with ICI plus platinum and paclitaxel compared to those treated with platinum and paclitaxel, although there was no statistical significance. In patients treated with ICI plus platinum and paclitaxel, the median PFS was 10.3 months and the median OS was not reached. Meanwhile, the median PFS and OS were 7.7 and 16.9 months in patients treated with platinum and paclitaxel. PFS (P = 0.036) and OS (P = 0.033) were increased in patients treated with ICI plus platinum and paclitaxel versus those treated with platinum and paclitaxel, which was verified by multivariate Cox regression analyses (both P < 0.05). No difference was observed in the occurrence of adverse events between patients receiving the two different treatments (all P > 0.05).
CONCLUSION: First-line ICI plus platinum and paclitaxel yields better treatment responses, longer survival, and non-differential adverse events versus first-line platinum and paclitaxel in advanced and recurrent cervical cancer patients.
BACKGROUND: Dementia is a significant cause of death in the older population and is becoming an important public health issue as the population ages and the prevalence of dementia increases. The Braden score is one of the most commonly used clinical tools to assess the risk of skin pressure injury in patients, and some studies have reported that it may reflect the state of frailty of patients. The present study attempted to explore the association between Braden score and 90-day mortality, pressure injury, and aspiration pneumonia in older patients with dementia in the intensive care unit (ICU).
METHODS: The study involved extracting crucial data from the Medical Information Market for Intensive Care IV (MIMIC-IV) database using Structured Query Language, with a license certificate obtained after completing the necessary training and examination available on the MIMIC-IV website. A retrospective analysis was performed on older patients with dementia, aged 65 or older, who were first admitted to the ICU. Ninth and tenth revision International Classification of Diseases codes were used to identify patients with dementia. The primary outcome was 90-day mortality. Cox proportional hazards models were used to determine the association between Braden score and death, and hazard ratios (HR) and 95% confidence intervals (CI) were calculated. Propensity score matching and E-value assessments were employed for sensitivity analysis.
RESULTS: A total of 2892 patients with a median age of approximately 85 years (interquartile range 78.74-89.59) were included, of whom 1625 were female (56.2%). Patients had a median Braden score of 14 (interquartile range 12-15) at ICU admission. Braden score at ICU admission was inversely associated with 90-day mortality risk after adjustment for demographics, severity of illness, treatment and medications, delirium, and sepsis (adjusted HR: 0.92, 95% CI: 0.87-0.98, p = 0.006). Patients were divided into two groups with a cut-off value of 15: high-risk group and low-risk group. Compared to the low-risk group (Braden score >15), the risk of 90-day mortality was significantly increased in the high-risk group (Braden score ≤15) (adjusted HR: 1.52, 95% CI: 1.10-2.09, p = 0.011, E-value: 2.01), the risk of pressure injury (adjusted OR: 2.62, 95% CI: 2.02-3.43, E-value: 2.62) and aspiration pneumonia (adjusted OR: 2.55, 95% CI: 1.84-3.61, E-value: 2.57) was also significantly higher.
CONCLUSIONS: The Braden score may be a quick and simple screening tool to identify the risk of adverse outcomes in critically ill older adults with dementia.
In Canada, cancer is the most common cause of death. Among solid organ cancers, brain tumors, depending upon type and grading, impose significant morbidity and mortality. In addition, cancer progression and recurrence is one of the most common complications in management of high-grade gliomas and among all, Glioblastoma Multiforme (GBM) is the most common and aggressive primary brain cancer. Many factors have been demonstrated to affect glioma progression . Some of the most consistently sited variables are age, grade of tumor, tumor size and location, molecular diagnosis, extent of resection, and chemotherapy and radiotherapy.

On the other hand, though, anesthesia remains an integral part of glioma surgeries, and two types of anesthetics (total intravenous agent, such as, propofol and volatile, such as sevoflurane) are commonly used during maintenance phase of general anesthesia (GA) across over all world; their effects on brain cancer progression are not yet investigated extensively. Recent studies have highlighted that there could be an association of anesthesia with cancer progression in other solid organs. Very few researches have been published demonstrating the relationship between type of anesthetic and glioma progression. One study found that exposure of glioblastoma stem cells to volatile agent (isoflurane) increased their migration capacity in vitro and increased their migration distance in vivo in animals. A second study found that exposure of glioma stem cells to sevoflurane increased tumor cell proliferation as well as tumor markers, most notably hypoxia-inducible factors (HIF), which are associated with cancer growth. Finally, a retrospective cohort study published in 2019 compared the progression free survival (PFS) of patients who underwent high-grade glioma surgery using two different types of anesthetics. They found that, for patients with low KPS, anesthesia maintenance with propofol yielded a longer PFS compared to sevoflurane (15). With this background, it seems propofol based anesthesia may limit the progression of brain cancer progression and therefore, the purpose is to evaluate type of anesthetics (propofol versus sevoflurane) as a factor responsible for glioma progression and survival characteristics. As the Investigators are planning for a future phase III study, it is imperative to understand thoroughly the details regarding feasibility, workflow, enrollment and drop out characteristics, reasons of deviation and adherence rates to anesthesia protocols and problems in follow ups. Therefore, this feasibility study is a path to a well-designed larger multicenter randomized study.
<P>PROBLEM TO BE SOLVED: To provide a method and an apparatus for supporting coordinated medical examinations which can prevent a medical examination mistake.  <P>SOLUTION: The coordinated medical examination support method is carried out by each operator in a different point retrieving and referring to the same treatment information from prepared portable storage media (21-1, 21-2), and in the coordinated medical examination support method, after preliminarily storing the same treatment information in storage means (12-1, 12-2) of respective medical examination termini (11-1, 11-2), a particular medical examination terminal transmits access information which specifies treatment information to be displayed to other medical examination terminal by a transmission medium 18. The other medical examination terminal retrieves the same treatment information from the storage means of the other medical examination termini based on the access information and displays it on a display unit (13-1, 13-2). Thereby, the same treatment information can be displayed automatically and correctly by the operation of a specified operator. The mistake of treatment information to be displayed, arising between a transmitting source and a transmitting destination can be prevented.  <P>COPYRIGHT: (C)2004,JPO
The present invention discloses a novel and improved composition and method of preparation of organic topical deodorant. The invention utilizes all readily available natural vegan ingredients for formulation of the deodorant product that results in effective elimination of body odor and retains good structural integrity without drying out or becoming rancid. Present invention achieves the main objectives by creating a unique composition comprised of pure corn starch, unbleached organic all-purpose flour, candelilla wax, virgin coconut oil, raw unfiltered organic apple cider vinegar and an optional fragrance. The disclosed ingredients are cooked in a double boiler at a certain temperature and in a manner that yields the claimed deodorant compound. With the process of this invention coconut oil can be substituted with other natural oils and fragrance can be altogether eliminated from the process without compromising deodorant's efficacy. Not only is the final deodorant compound safe for topical use, but also due to its unique combination of natural ingredients, no harmful by-products are formed during the process of preparation. This method of preparation thus gives the final product an environmental advantage over the other similar products known in the prior art.
Participants will have a multiparametric prostate MRI and diagnostic prostate biopsy with confirmed localized prostate tumor prior to HIFU. HIFU consists of a single treatment. All participants will have a postoperative visit at 3 days after surgery, followed by phone calls at 1 week, 2 weeks and 4 weeks, followed by office visits at 6 weeks, 3 months, 6 months, 9 months, 1 year, 2 years and 3 years. Participants will be followed indefinitely as per standard of care.